Oliver Sartor, MD

Articles

Emerging Targeted Therapies in mCRPC

May 12th 2022

Before closing out their discussion, experts review novel targeted agents under investigation in metastatic CRPC.

Defining Unmet Needs in the Management of mCRPC

May 12th 2022

Experts share insight on the greatest unmet needs in treating patients with metastatic castration-resistant prostate cancer.

Ongoing PSMA-Targeted Radioligand Trials in mCRPC

May 5th 2022

Andrew J. Armstrong, MD, MSc, breaks down ongoing prostate cancer clinical trials looking at targeted radioligand therapies.

Metastatic CRPC: Considerations for Radiotherapy

May 5th 2022

Oliver Sartor, MD, considers the respective roles of Lu-PSMA-617 and radium-223 as radiotherapy in the setting of mCRPC.

Potential Role of Lu-PSMA-617 in mCRPC

April 28th 2022

Expert perspectives on where Lu-PSMA-617 therapy may fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

VISION Trial: Lu-PSMA-617 in mCRPC

April 28th 2022

A comprehensive review of the design and results of VISION, which analyzed Lu-PSMA-617 therapy in patients with mCRPC.

Role of Radium-223 in Treating mCRPC

April 21st 2022

Expert Scott Tagawa, MD, MS, FACP, details the role of radium-223 in treating metastatic CRPC and highlights real-world experiences.

Patient Factors in Selecting Therapy for mCRPC

April 21st 2022

Shared insight on the key factors that play into the selection of therapy for patients with metastatic castration-resistant prostate cancer.

Metastatic CRPC Treatment Armamentarium

April 14th 2022

A detailed review of the available pharmacologic agents used to treat patients with metastatic castration-resistant prostate cancer.

Role of Novel Imaging in Prostate Cancer

April 14th 2022

A brief discussion on how novel imaging strategies are being used to inform the treatment of patients with prostate cancer.

Phenotypic Biomarkers in the Management of Prostate Cancer

April 6th 2022

Expert perspectives on phenotypic biomarkers in prostate cancer and their role in comparison to genotypic biomarkers.

Background on Prostate Cancer and Biomarker Testing

April 6th 2022

Broad discussion on the role of biomarker testing in prostate cancer, particularly how it has helped to inform therapy selection and patient management.

Dr. Sartor on Conclusions and Future of Sipuleucel-T in Prostate Cancer

August 28th 2017

Oliver Sartor, MD, medical oncologist at Tulane University School of Medicine, discusses conclusions drawn from an analysis of African-American patients receiving sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer and the potential for combinations with this agent.

Dr. Sartor on the Science of Sipuleucel-T for Prostate Cancer

August 18th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the science behind the results of a study investigating sipuleucel-T (Provenge) for patients with castration-resistant prostate cancer (CRPC).

Dr. Sartor on the Next Steps with Sipuleucel-T for Prostate Cancer

August 10th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Dr. Sartor on Remaining Questions With Sipuleucel-T in mCRPC

July 21st 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer.

Dr. Sartor on the Implications of the Analysis of Sipuleucel-T in Prostate Cancer

June 27th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Dr. Sartor on Sipuleucel-T in mCRPC

May 24th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Dr. Sartor on Mechanism of Action and Safety of Radium-223 in mCRPC

June 21st 2016

Oliver Sartor, MD, medical director of Tulane Cancer Center, discusses the mechanism of action of radium-223 dichloride (Xofigo) as well as its safety profile for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Sartor on Significance of Radium-223 for Community Oncologists

September 16th 2015

Oliver Sartor, MD, medical oncologist, Tulane University School of Medicine, discusses key points for community oncologists regarding radium-223 for the treatment of prostate cancer.